• Registrational Phase 3 Clinical Trial for Diabetic Foot Infections in Indonesia well underway
• Positive Efficacy Data of Inhaled RECCE® 327 in Hospital/Ventilator-Acquired Pneumonia (HAP/VAP) in Mice Models
• Hong Kong Patent Granted for RECCE® Anti-Infectives

Recce Pharmaceuticals Ltd has released its Q2 FY2026 results and operational highlights. The company has continued to progress its Phase 3 Clinical Trial for Diabetic Foot Infections (DFI) in Indonesia, with further patient dosing across activated clinical trial sites. The trial has a target of 155 patients as an approvable interim data-point with up to 310 DFI patients randomised to receive either RECCE® 327 Topical Gel (R327G) or placebo overall. The company also reported positive preclinical data from an ongoing research program on the therapeutic efficacy of RECCE® 327 (R327) in a validated model of Hospital/Ventilator-Acquired Pneumonia (HAP/VAP) caused by carbapenem-resistant Acinetobacter baumannii. Additionally, the Hong Kong Special Administrative Region has formally granted Patent Family 4 for Recce's Anti-Infectives, expiry 2041. The company also announced the passing of its founder and inventor of Recce's technology platform, Dr Graham Melrose. Financially, the company ended the quarter with a cash balance of AUD $0.4 million, with a further AUD $5.3 million R&D rebate received post quarter end and an additional AUD $3.5 million expected this quarter. Recce also received an Advanced Overseas Finding for up to AUD $85 million for Synthetic Antibiotic Research & Development (R&D) applicable expenditure by the Department of Industry, Science and Resources.

Supported by strong financial momentum, advancing clinical data, and growing global recognition, Recce enters the coming quarters well positioned to capitalise on multiple commercial and strategic catalysts.